Frontage Holdings Corp (HKSE:01521) Stock Price, Trades & News

Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.31
Equity-to-Asset	0.64
Debt-to-Equity	0.37
Debt-to-EBITDA	6.64
Interest Coverage	2.59
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.66	Distress Grey Safe
Beneish M-Score	-2.68	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

9/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	1.8
	3-Year EBITDA Growth Rate	-7.4
	3-Year EPS without NRI Growth Rate	-23.3
	3-Year FCF Growth Rate	31.9
	3-Year Book Growth Rate	1.8
	Future 3-5Y Total Revenue Growth Rate Estimate	8.84

Momentum Rank

4/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	57.71
	9-Day RSI	54.26
	14-Day RSI	53.13
	3-1 Month Momentum %	-23.64
	6-1 Month Momentum %	-16.83
	12-1 Month Momentum %	-22.22

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	1.33
	Quick Ratio	1.31
	Cash Ratio	0.38
	Days Inventory	5.72
	Days Sales Outstanding	87.89
	Days Payable	19.51

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	0.5
	Shareholder Yield %	9.24

Profitability Rank

9/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	26.96
	Operating Margin %	7.64
	Net Margin %	2.65
	EBITDA Margin %	7.46
	FCF Margin %	12.57
	OCF Margin %	17.1
	ROE %	2
	ROA %	1.24
	ROIC %	2.31
	3-Year ROIIC %	-28.53
	ROC (Joel Greenblatt) %	9.59
	ROCE %	4.37
	Years of Profitability over Past 10-Year	10
	Moat Score	4

GF Value Rank

8/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	37.69
	Forward PE Ratio	25.13
	PE Ratio without NRI	16.07
	Shiller PE Ratio	16.33
	Price-to-Owner-Earnings	11.4
	PEG Ratio	2.4
	PS Ratio	0.99
	PB Ratio	0.74
	Price-to-Tangible-Book	1.88
	Price-to-Free-Cash-Flow	7.9
	Price-to-Operating-Cash-Flow	5.81
	EV-to-EBIT	17.72
	EV-to-Forward-EBIT	24.65
	EV-to-EBITDA	17.72
	EV-to-Revenue	1.32
	EV-to-Forward-Revenue	6.14
	EV-to-FCF	10.51
	Price-to-GF-Value	0.64
	Price-to-Projected-FCF	0.53
	Price-to-Peter-Lynch-Fair-Value	2.39
	Price-to-Graham-Number	1.15
	Earnings Yield (Greenblatt) %	5.64
	FCF Yield %	12.69
	Forward Rate of Return (Yacktman) %	13.37

Financials (Next Earnings Date:2026-08-28 Est.)

Annual Quarterly TTM

HKSE:01521's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Frontage Holdings Corp Executives

Details

GF Value™: HK$1.53

HKSE:01521

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 5 Severe warning signs with 01521. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil HK$)	2,005.843
	EPS (TTM) (HK$)	0.026
	Beta	0.6435
	3-Year Sharpe Ratio	-0.3
	3-Year Sortino Ratio	-0.48
	Volatility %	66.42
	14-Day RSI	53.13
	14-Day ATR (HK$)	0.056622
	20-Day SMA (HK$)	0.977
	12-1 Month Momentum %	-22.22
	52-Week Range (HK$)	0.68 - 1.87
	Shares Outstanding (Mil)	2,027.73

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Frontage Holdings Corp Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Frontage Holdings Corp Stock Events

Financials Calendars

Event	Date	Price (HK$)
Second quarter earnings results for 2026	2026-08-28	In 55 days
General meeting for 2025	2026-06-02 10:00	0.72 (+5.88%)
Annual report for 2025	2026-04-28	1.01 (-0.98%)
Fourth quarter earnings results for 2025	2026-03-30	1.14 (+0.00%)
Second quarter earnings results for 2025	2025-08-28	1.38 (-4.83%)
General meeting for 2024	2025-05-28 10:00	1.11 (-5.13%)
Annual report for 2024	2025-04-24	1.20 (+6.19%)
Fourth quarter earnings results for 2024	2025-03-27	1.05 (+1.94%)
Second quarter earnings results for 2024	2024-08-28	0.64 (-1.54%)

Show

Entries

Frontage Holdings Corp Frequently Asked Questions

What is Frontage Holdings Corp(HKSE:01521)'s stock price today?

The current price of HKSE:01521 is HK$0.98. The 52 week high of HKSE:01521 is HK$1.87 and 52 week low is HK$0.68.

When is next earnings date of Frontage Holdings Corp(HKSE:01521)?

The next earnings date of Frontage Holdings Corp(HKSE:01521) is 2026-08-28 Est..

Does Frontage Holdings Corp(HKSE:01521) pay dividends? If so, how much?

Frontage Holdings Corp(HKSE:01521) does not pay dividend.

Press Release

	Subject	Date
	Frontage Announces Expansion of Business in Canada with New Leadership	2025-07-01
	Expansion of Frontage Laboratories Continues with Launch of New State-of-the-Art CRDMO Facility in Exton, PA	2025-06-02
	EPNextS Group and Frontage Laboratories, Inc. Announce Collaboration in Early Phase Clinical Trials in the United States to Improve "Drug Lag" and "Drug Loss" Issues in Japan	2024-03-26
	Frontage Laboratories Acquires Accelera S.r.l.'s Bioanalytical and DMPK Businesses	2024-01-02
	Frontage announces the appointment of Mr. Henry Gao as President of Asia Pacific	2024-01-02
	Frontage Acquires Nucro-Technics Inc. and Nucro-Technics Holdings, Inc.	2023-08-16
	Frontage Receives Multiple 2023 CRO Leadership Awards	2023-05-01
	Frontage Announces CEO and President Promotions	2023-01-03
	Frontage Partners with Eisai and Biogen to Complete the Clarity AD study for the Alzheimer's Drug, Lecanemab	2022-12-12
	Frontage Central Labs is Awarded the Prestigious CAP Accreditation from the College of American Pathologists	2022-11-29

10/Page

Articles on Frontage Holdings Corp

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.